Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Cotton

Showing results (441-450 of 474) with videos related to

Pageof 48
Sort By:
Lancet (London, England)|November 12, 2013
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trialMark F Cotton, Avy Violari, Kennedy Otwombe, et al.
The New England Journal of Medicine|October 15, 2010
Antiretroviral treatment for children with peripartum nevirapine exposurePaul Palumbo, Jane C Lindsey, Michael D Hughes, et al.
AIDS (London, England)|November 8, 2017
Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trialMichael J Boivin, Linda Barlow-Mosha, Miriam C Chernoff, et al.
The Lancet. HIV|April 15, 2024
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm studyCarina A Rodriguez, Eva Natukunda, Renate Strehlau, et al.
The Lancet. HIV|October 11, 2025
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trialAdrie Bekker, Nicolas Salvadori, Helena Rabie, et al.
Antimicrobial Agents and Chemotherapy|October 26, 2023
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026sMarije Van Schalkwyk, Adrie Bekker, Eric Decloedt, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 6, 2026
Proviral HIV-1 DNA Below Detection in Early Treated Adolescents After Prior Treatment InterruptionKavidha Reddy, Louise Kuhn, Shaun Barnabas, et al.
The Pediatric Infectious Disease Journal|September 16, 2014
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmissionJane C Lindsey, Michael D Hughes, Avy Violari, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|September 4, 2020
Leadership and early strategic response to the SARS-CoV-2 pandemic at a COVID-19 designated hospital in South AfricaA Parker, S Karamchand, N Schrueder, et al.
Antimicrobial Agents and Chemotherapy|July 31, 2025
Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s studyMarije Van Schalkwyk, Adrie Bekker, Eric Decloedt, et al.
Pageof 48

Showing results (441-450 of 474) with videos related to

Sort By:
Pageof 48
Lancet (London, England)|November 12, 2013
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trialMark F Cotton, Avy Violari, Kennedy Otwombe, et al.
The New England Journal of Medicine|October 15, 2010
Antiretroviral treatment for children with peripartum nevirapine exposurePaul Palumbo, Jane C Lindsey, Michael D Hughes, et al.
AIDS (London, England)|November 8, 2017
Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trialMichael J Boivin, Linda Barlow-Mosha, Miriam C Chernoff, et al.
The Lancet. HIV|April 15, 2024
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm studyCarina A Rodriguez, Eva Natukunda, Renate Strehlau, et al.
The Lancet. HIV|October 11, 2025
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trialAdrie Bekker, Nicolas Salvadori, Helena Rabie, et al.
Antimicrobial Agents and Chemotherapy|October 26, 2023
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026sMarije Van Schalkwyk, Adrie Bekker, Eric Decloedt, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 6, 2026
Proviral HIV-1 DNA Below Detection in Early Treated Adolescents After Prior Treatment InterruptionKavidha Reddy, Louise Kuhn, Shaun Barnabas, et al.
The Pediatric Infectious Disease Journal|September 16, 2014
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmissionJane C Lindsey, Michael D Hughes, Avy Violari, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|September 4, 2020
Leadership and early strategic response to the SARS-CoV-2 pandemic at a COVID-19 designated hospital in South AfricaA Parker, S Karamchand, N Schrueder, et al.
Antimicrobial Agents and Chemotherapy|July 31, 2025
Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s studyMarije Van Schalkwyk, Adrie Bekker, Eric Decloedt, et al.
Pageof 48